Back

Timothy K Lu

Timothy K Lu is affiliated with the Massachusetts Institute of Technology.[1]He specializes in electrical engineering and biological engineering.[2]He is a member of Synthetic Biology Group.[3]

Timothy K. Lu, M.D., Ph.D. is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and Department of Biological Engineering at MIT.[4]His motivation to study medicine stemmed from wanting to find applications for his research.[5]He soon became intrigued by the idea of programming biological systems.[6]Dr. Lu is a frequent speaker on phage technology at prominent scientific conferences and has authored multiple phage-related articles published in peer-reviewed journals.[7]Starting up a number of companies and with a particular interest in synthetic biology, he was selected by MIT Technology Review as one of its 'Top Innovators under 35' in 2010.[8]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Timothy K Lu on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Massachusetts Institute of Technology

Employer

  • 4

    Events

  • 509

    Mentions

  • 143

    Docs

Recent events

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

MIT, Hebrew U team's screen for cell type-specific synthetic promoters  Timothy Lu and colleagues at Massachusetts Institute of Technology and Hebrew University of Jerusalem described a method in a Nature Communications paper that identifies synthetic promoters for use in any desired cell type or state, for example in stem cells vs. differentiated cells or in normal vs. cancerous cells. The authors have filed a patent application for the strategy, which could be used to pick synthetic promoters for cell type-dependent gene therapies and production of stem cell-derived therapies.[16]

07/02/2019

Event Date

Genetically engineered bacteria lets ingestible sensor monitor gut health

Now a team of researchers at MIT has produced a novel "bacteria on a chip" system that combines genetically engineered bacteria that can detect intestinal bleeding with an ingestible electronic circuit that can wirelessly send a signal to a nearby computer. "By combining engineered biological sensors together with low-power wireless electronics, we can detect biological signals in the body and in near real-time, enabling new diagnostic capabilities for human health applications," says Timothy Lu, one of the MIT researchers working on the project. To begin, the team genetically engineered a probiotic strain of E. coli bacteria to respond to the presence of a chemical compound call heme, a compound found within red-blood cells and has been shown to be a reliable biomarker of internal bleeding. Initial tests found the device accurately detected the presence of blood in the stomach of pigs, and the researchers have already developed two more bacterial sensors pointing to other potential future diagnostic uses.[14152]

05/25/2018

Event Date

With largest transpacific seed round, S.F. startup aims to rev up drug discovery

Engine, which has three people in San Francisco, initially is focusing on liver cancer, ovarian cancer and neurodegenerative diseases, Jeff Lu said. But, he added, the concept can be extended to repurpose already-approved drugs, identify potential targets for drug discovery, direct the right drug at the right time to the right patient based on their genetic makeup, and analyze disease pathways. "We want to see it used as broadly as possible," Jeff Lu said. Much of the challenge of traditional drug discovery is based in an insufficient understanding of how biology is networked, Jeff Lu said.[1213]

01/31/2018

Event Date

References

  1. 12
    With largest transpacific seed round, S.F. startup aims to rev up drug discovery2018-01-31